@article{WiegeringAndresSchlegeletal.2013,
  author    = {Wiegering, Verena and Andres, Oliver and Schlegel, Paul G. and Deinlein, Frank and Eyrich, Matthias and Sturm, Alexander},
  title     = {Hyperfibrinolysis and acquired factor XIII deficiency in newly diagnosed pediatric malignancies},
  series = {Haematologica},
  volume    = {98},
  journal   = {Haematologica},
  number    = {8},
  doi       = {10.3324/haematol.2013.089045},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130569},
  pages     = {E90-E91},
  year      = {2013},
  abstract  = {No abstract available},
  language  = {en}
}
@article{WiegeringSchmidAndresetal.2014,
  author    = {Wiegering, Verena and Schmid, Sophie and Andres, Oliver and Wirth, Clemens and Wiegering, Armin and Meyer, Thomas and Winkler, Beate and Schlegel, Paul G. and Eyrich, Matthias},
  title     = {Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience},
  doi       = {10.1186/2052-1839-14-18},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-110476},
  year      = {2014},
  abstract  = {Background Reliable central venous access (CVC) is essential for hematology-oncology patients since frequent puncture of peripheral veins—e.g., for chemotherapy, antibiotic administration, repeated blood sampling, and monitoring—can cause unacceptable pain and psychological trauma, as well as severe side effects in cases of extravasation of chemotherapy drugs. However, CVC lines still carry major risk factors, including thrombosis, infection (e.g., entry site, tunnel, and luminal infections), and catheter dislocation, leakage, or breakage. Methods Here we performed a retrospective database analysis to determine the incidence of CVC-associated thrombosis in a single-center cohort of 448 pediatric oncologic patients, and to analyze whether any subgroup of patients was at increased risk and thus might benefit from prophylactic anticoagulation. Results Of the 448 patients, 269 consecutive patients received a CVC, and 55 of these 269 patients (20\%) also had a thrombosis. Of these 55 patients, 43 had at least one CVC-associated thrombosis (total number of CVC-associated thrombosis: n = 52). Among all patients, the median duration of CVC exposure was 464 days. Regarding exposure time, no significant difference was found between patients with and without CVC-associated thrombosis. Subclavia catheters and advanced tumor stages seem to be the main risk factors for the development of CVC-associated thrombosis, whereas pharmacologic prophylaxis did not seem to have a relevant impact on the rate of thrombosis. Conclusions We conclude that pediatric surgeons and oncologists should pay close attention to ensuring optimal and accurate CVC placement, as this appears the most effective tool to minimize CVC-associated complications.},
  language  = {en}
}
@article{KrakowCrescimoneBartelsetal.2019,
  author    = {Krakow, S{\"o}ren and Crescimone, Marie L. and Bartels, Charlotte and Wiegering, Verena and Eyrich, Matthias and Schlegel, Paul G. and W{\"o}lfl, Matthias},
  title     = {Re-expression of CD14 in response to a combined IL-10/TLR stimulus defines monocyte-derived cells with an immunoregulatory phenotype},
  series = {Frontiers in Immunology},
  volume    = {10},
  journal   = {Frontiers in Immunology},
  number    = {1484},
  doi       = {10.3389/fimmu.2019.01484},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201537},
  year      = {2019},
  abstract  = {Interleukin 10 is a central regulator of the antigen-presenting function of myeloid cells. It exerts immunomodulatory effects in vivo and induces a regulatory phenotype in monocyte-derived cells in vitro. We analyzed phenotype and function of monocytic cells in vitro in relation to the cytokine milieu and the timing of TLR-based activation. In GM-CSF/IL-4 cultured human monocytic cells, we identified two, mutually exclusive cell populations arising from undifferentiated cells: CD83\(^+\) fully activated dendritic cells and CD14\(^+\) macrophage like cells. Re-expression of CD14 occurs primarily after a sequential trigger with a TLR signal following IL-10 preincubation. This cell population with re-expressed CD14 greatly differs in phenotype and function from the CD83+ cells. Detailed analysis of individual subpopulations reveals that exogenous IL-10 is critical for inducing the shift toward the CD14\(^+\) population, but does not affect individual changes in marker expression or cell function in most cases. Thus, plasticity of CD14 expression, defining a subset of immunoregulatory cells, is highly relevant for the composition of cellular products (such as DC vaccines) as it affects the function of the total product.},
  language  = {en}
}